An Analog of a Dipeptide-like Structure of FK506 Increases Glial Cell Line-derived Neurotrophic Factor Expression Through CAMP Response Element-binding Protein Activated by Heat Shock Protein 90/Akt Signaling Pathway
Overview
Authors
Affiliations
Glial cell line-derived neurotrophic factor (GDNF) is an important neurotrophic factor that has therapeutic implications for neurodegenerative disorders. We previously showed that leucine-isoleucine (Leu-Ile), an analog of a dipeptide-like structure of FK506 (tacrolimus), induces GDNF expression both in vivo and in vitro. In this investigation, we sought to clarify the cellular mechanisms underlying the GDNF-inducing effect of this dipeptide. Leu-Ile transport was investigated using fluorescein isothiocyanate-Leu-Ile in cultured neurons, and the results showed the transmembrane mobility of this dipeptide. By liquid chromatography-mass spectrometry and quartz crystal microbalance assay, we identified heat shock cognate protein 70 as a protein binding specifically to Leu-Ile, and molecular modeling showed that the ATPase domain is the predicted binding site. Leu-Ile stimulated Akt phosphorylation, which was attenuated significantly by heat shock protein 90 (Hsp90) inhibitor geldanamycin (GA). Moreover, enhanced interaction between phosphorylated Akt and Hsp90 was detected by immunoprecipitation. Leu-Ile elicited an increase in cAMP response element binding protein (CREB) phosphorylation, which was inhibited by GA, indicating that CREB is a downstream target of Hsp90/Akt signaling. Leu-Ile elevated the levels of GDNF mRNA and protein expression, whereas inhibition of CREB blocked such effects. Leu-Ile promoted the binding activity of phosphorylated CREB with cAMP response element. These findings show that CREB plays a key role in transcriptional regulation of GDNF expression induced by Leu-Ile. In conclusion, Leu-Ile activates Hsp90/Akt/CREB signaling, which contributes to the upregulation of GDNF expression. It may represent a novel lead compound for the treatment of dopaminergic neurons or motoneuron diseases.
Wang C, Qiu Z, Zhang P, Tang X Curr Neuropharmacol. 2023; 21(11):2251-2265.
PMID: 37132111 PMC: 10556388. DOI: 10.2174/1570159X21666230502123729.
Zhan Y, Li J, Sun J, Zhang W, Li Y, Cui D Front Genet. 2019; 10:301.
PMID: 31019527 PMC: 6458246. DOI: 10.3389/fgene.2019.00301.
He X, Yang S, Zhang R, Hou L, Xu J, Hu Y Front Cell Neurosci. 2019; 13:18.
PMID: 30804756 PMC: 6371654. DOI: 10.3389/fncel.2019.00018.
Nam J, Leem E, Jeon M, Jeong K, Park J, Jung U Mol Neurobiol. 2014; 51(2):487-99.
PMID: 24859383 DOI: 10.1007/s12035-014-8729-2.
Glial modulators as potential treatments of psychostimulant abuse.
Beardsley P, Hauser K Adv Pharmacol. 2014; 69:1-69.
PMID: 24484974 PMC: 4103010. DOI: 10.1016/B978-0-12-420118-7.00001-9.